biostudies-literatureUnknown39(5)Menzies-Gow AAstraZeneca Schweiz<h4>Introduction</h4>Consensus definitions for clinical remission and super-response were recently established for severe asthma. Benralizumab is an interleukin-5 (IL-5) receptor α-directed monoclonal antibody for severe, uncontrolled asthma; efficacy and safety were demonstrated in previous pivotal phase 3 trials (SIROCCO, CALIMA, ZONDA). This analysis applied a composite remission definition to characterize individual responses to benralizumab after 6 and 12 months.<h4>Methods</h4>In previous phase 3 studies, eligible patients were those with severe, uncontrolled asthma receiving medium- or high-dosage inhaled corticosteroids plus long-acting β₂-agonists. This post hoc analysis included patients randomized to the approved benralizumab dose and not receiving oral corticosteroidAdvances in therapy2065-2084https://www.ebi.ac.uk/biostudies/studies/S-EPMC9056458biostudies-literatureClinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with Benralizumab.PMC9056458Hoyte FLBarker PKreindler JBrooks CLJison MKatial RPrice DBMenzies-Gow ACohen DPapeleu PfalseClinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with Benralizumab.<h4>Introduction</h4>Consensus definitions for clinical remission and super-response were recently established for severe asthma. Benralizumab is an interleukin-5 (IL-5) receptor α-directed monoclonal antibody for severe, uncontrolled asthma; efficacy and safety were demonstrated in previous pivotal phase 3 trials (SIROCCO, CALIMA, ZONDA). This analysis applied a composite remission definition to characterize individual responses to benralizumab after 6 and 12 months.<h4>Methods</h4>In previous phase 3 studies, eligible patients were those with severe, uncontrolled asthma receiving medium- or high-dosage inhaled corticosteroids plus long-acting β₂-agonists. This post hoc analysis included patients randomized to the approved benralizumab dose and not receiving oral corticosteroid2022-01-01T00:00:00Z2022 May2026-05-31T14:03:56.318Z2024-11-19T21:20:37.56ZS-EPMC90564583528723110.1007/s12325-022-02098-1